InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,728.80
(
0.41%
)
US TECH 100
19,537.60
(
0.21%
)
Dow Jones
42,052.19
(
0.69%
)
Brent Oil
75.26
(
1.60%
)
Bitcoin
68,737.03
(
-0.01%
)
Post# of 253514
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

dav1234

Send PM Follow Ignore
Followers 97
Posts 92809
Boards Moderated 4
Alias Born 10/29/2007

dav1234

Re: DewDiligence post# 156311

Sunday, 02/03/2013 1:43:32 PM

Sunday, February 03, 2013 1:43:32 PM

Post# of 253514
Pfizer (PFE) animal-health spin-off Zoetis (ZTS) forecasts annual growth of 5.7% through 2016, CEO Juan Ramon Alaix tells Bloomberg. He points out that drug failure rates are lower than with human medicines, as there are fewer safety concerns and because animals don't live as long. "Side effects are very rare in our industry, especially in livestock," Alaix says. Zoetis had a stonking NYSE debut on Friday, jumping 19% to close at $31.01 for a market cap of $15.51B
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up